TY - JOUR
T1 - An analysis of original research contributions toward FDA-approved drugs
AU - Patridge, Eric V.
AU - Gareiss, Peter C.
AU - Kinch, Michael S.
AU - Hoyer, Denton W.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/10
Y1 - 2015/10
N2 - Academic researchers shaped the landscape of drug discovery for nearly two centuries, and their efforts initiated programs for more than half of the US Food and Drug Administration (FDA)-approved new molecular entities (NMEs). During the first 50 years of the 20th century, contributions from industry-based discovery programs steadily increased, stabilizing near half of all first publications for NMEs. Although academia and industry have made similar contributions to the discovery of FDA-approved NMEs, there remains a substantial difference in the gap-to-approval; on average, industry NMEs are 12 years closer to market at the time of the first publication. As more drug discovery efforts shift from industry to academia, including high-throughput screening resources, academia could have an increasingly crucial role in drug discovery.
AB - Academic researchers shaped the landscape of drug discovery for nearly two centuries, and their efforts initiated programs for more than half of the US Food and Drug Administration (FDA)-approved new molecular entities (NMEs). During the first 50 years of the 20th century, contributions from industry-based discovery programs steadily increased, stabilizing near half of all first publications for NMEs. Although academia and industry have made similar contributions to the discovery of FDA-approved NMEs, there remains a substantial difference in the gap-to-approval; on average, industry NMEs are 12 years closer to market at the time of the first publication. As more drug discovery efforts shift from industry to academia, including high-throughput screening resources, academia could have an increasingly crucial role in drug discovery.
UR - http://www.scopus.com/inward/record.url?scp=84944513136&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2015.06.006
DO - 10.1016/j.drudis.2015.06.006
M3 - Short survey
C2 - 26113307
AN - SCOPUS:84944513136
SN - 1359-6446
VL - 20
SP - 1182
EP - 1187
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 10
ER -